Profile data is unavailable for this security.
About the company
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
- Revenue in AUD (TTM)16.23m
- Net income in AUD-40.56m
- Incorporated2020
- Employees87.00
- LocationAVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
- Phone+1 (661) 367-9170
- Websitehttps://www.avitamedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dimerix Ltd | 181.28k | -10.87m | 197.86m | 0.00 | -- | 89.36 | -- | 1,091.44 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
Race Oncology Ltd | 885.59k | -11.17m | 202.72m | -- | -- | 9.76 | -- | 228.91 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
Probiotec Ltd | 221.22m | 8.69m | 230.15m | 111.00 | 27.26 | 2.61 | 9.61 | 1.04 | 0.1038 | 0.1038 | 2.64 | 1.09 | 0.9483 | 7.03 | 6.99 | -- | 3.72 | 4.58 | 5.36 | 5.94 | 29.95 | 30.21 | 3.93 | 5.73 | 1.09 | 3.33 | 0.4937 | 47.90 | 17.39 | 23.10 | -19.61 | 20.84 | 12.97 | 18.77 |
Cogstate Ltd | 63.27m | 8.40m | 239.99m | 61.00 | 31.14 | 4.15 | 19.05 | 3.79 | 0.045 | 0.045 | 0.3428 | 0.3374 | 0.7757 | -- | 5.58 | -- | 10.30 | 6.01 | 13.84 | 9.22 | 54.69 | 51.50 | 13.28 | 7.26 | -- | -- | 0.0135 | 0.00 | -8.62 | 7.25 | -52.56 | -- | -5.06 | -- |
AVITA Medical Inc | 16.23m | -40.56m | 342.79m | 87.00 | -- | 228.21 | -- | 21.13 | -0.0288 | -0.0288 | 0.0114 | 0.0117 | 0.1882 | 2.86 | 5.89 | 186,506.20 | -47.05 | -121.83 | -51.04 | -152.54 | 78.72 | 73.46 | -249.98 | -633.80 | 15.22 | -197.63 | 0.0301 | -- | 543.96 | 24.92 | -112.85 | -- | 88.43 | -- |
Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 393.78m | 1.00 | -- | 8.52 | -- | 1,965.19 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
Opthea Ltd | 178.42k | -246.24m | 407.63m | 5.00 | -- | -- | -- | 2,284.60 | -0.472 | -0.472 | 0.0003 | -0.1079 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
PYC Therapeutics Ltd | 21.54m | -21.65m | 489.94m | 23.00 | -- | 13.11 | -- | 22.74 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
Holder | Shares | % Held |
---|---|---|
Montgomery Investment Management Pty Ltd.as of 16 Sep 2022 | 4.59m | 3.57% |
Sandhurst Trustees Ltd.as of 31 Jan 2024 | 278.70k | 0.22% |
Schr�der Equities GmbHas of 31 Jan 2024 | 45.00k | 0.04% |